All In MedTech

FDA Clearance Tracker · P040044-S045

MYNX VASCULAR CLOSURE DEVICE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 22, 2013 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 22, 2013

Approved

Time to decision

250 days

Received Nov 14, 2012. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P040044-S045
Device name
MYNX VASCULAR CLOSURE DEVICE
Applicant location
Miami Lakes, FL
Received
Nov 14, 2012
Decided
Jul 22, 2013
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P040044

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code MGB

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A MANUFACTURING SITE LOCATED IN SANTA CLARA, CALIFORNIA.

Source documents

Other decisions for Cordis US Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.